PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-3.38%
Negative ROE while Drug Manufacturers - Specialty & Generic median is 0.83%. Seth Klarman would investigate if capital structure or industry issues are at play.
-3.00%
Negative ROA while Drug Manufacturers - Specialty & Generic median is 0.36%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-3.72%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.94%. Seth Klarman would investigate whether a turnaround is viable.
64.59%
Gross margin 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 54.41%. Mohnish Pabrai would verify if a unique value chain offers pricing benefits.
-23.43%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 3.33%. Seth Klarman would look for a path to operational turnaround.
-21.27%
Negative net margin while Drug Manufacturers - Specialty & Generic median is 2.70%. Seth Klarman would see if cost cuts or revenue growth can fix losses.